Related Experiment Video

Updated: Jun 27, 2026

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
08:54

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

[Trends in development of new antifungal agents in Japan]

Yoshihito Niki1

  • 1Department of Clinical Infectious Diseases, School of Medicine, Showa University.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|December 17, 2008
PubMed

Insights

New antifungal drugs show promise but deep-seated fungal infections remain challenging. Novel approaches like immunotherapy are needed alongside new antifungals to improve treatment outcomes.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Recent advancements in antifungal agents like micafungin, voriconazole, and ambisome have been introduced since 2001.
  • Despite new treatments, deep-seated fungal infections, such as pulmonary aspergillosis, remain difficult to manage, with success rates around 40-50%.
  • Emerging challenges include antifungal resistance, breakthrough infections, and economic constraints.

Purpose of the Study:

  • To review the current landscape of antifungal treatments in Japan.
  • To highlight the limitations of existing and upcoming antifungal agents.
  • To advocate for the consideration of novel therapeutic strategies.

Main Methods:

  • Literature review of antifungal agents and treatment outcomes.
  • Analysis of challenges in managing deep-seated fungal infections.
  • Discussion of emerging antifungal drugs and treatment paradigms.

Main Results:

  • New antifungal agents have been approved, with others like caspofungin and posaconazole entering clinical trials in Japan.
  • Treatment success for pulmonary aspergillosis remains suboptimal.
  • Antifungal resistance, breakthrough infections, and cost present significant hurdles.

Conclusions:

  • While new antifungal drugs offer potential, they are insufficient to overcome all challenges in treating deep-seated fungal infections.
  • Integrated treatment approaches, including immunotherapy and supportive therapies, should be explored to enhance patient outcomes.

More Related Videos

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance08:45

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Published on: December 28, 2017

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Chemical Agents for Microbial Control01:27

Chemical Agents for Microbial Control

Chemicals play important roles in controlling microbial growth by targeting microbial structures and functions as sanitizers, antiseptics, disinfectants, and sterilants.Alcohols are commonly used sanitizers, effectively disrupting lipid membranes, which compromises cell integrity. They are also used as antiseptics and disinfectants due to their rapid action and versatility.Phenols and their derivatives phenolics , known for denaturing proteins and disrupting cell membranes, are particularly...